Positive results from Eisai and Biogen Alzheimer's trial

Eisai and Biogen have announced positive results from a trial of lecanemab to treat mild cognitive impairment due to Alzheimer’s disease. 

Related Keywords

Japan ,Haruo Naito ,Michel Vounatsos ,Eisai Co Ltd ,Drug Administration ,Devices Agency ,Clinical Trials On Alzheimer Congress ,Biogen Inc ,Japan Pharmaceuticals ,Ad Cooperative Study ,Clinical Trials ,Daily Living Scale ,Mild Cognitive Impairment ,Biologics License Application ,Prescription Drugs User Fee Act ,Approval Pathway ,Medical Devices Agency ,